REYON Pharmaceutical Co., Ltd.

KOSE:A102460 Stock Report

Market Cap: ₩230.4b

REYON Pharmaceutical Valuation

Is A102460 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A102460 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A102460 (₩12560) is trading above our estimate of fair value (₩2709.36)

Significantly Below Fair Value: A102460 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A102460?

Key metric: As A102460 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A102460. This is calculated by dividing A102460's market cap by their current revenue.
What is A102460's PS Ratio?
PS Ratio1.5x
Sales₩149.84b
Market Cap₩230.36b

Price to Sales Ratio vs Peers

How does A102460's PS Ratio compare to its peers?

The above table shows the PS ratio for A102460 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.8x
A001630 Chong Kun Dang Holdings
0.2x5.0%₩232.1b
A058820 CMG Pharmaceutical
2.5xn/a₩239.2b
A009290 Kwang Dong Pharmaceutical
0.1xn/a₩224.9b
A096760 JW Holdings
0.2xn/a₩217.3b
A102460 REYON Pharmaceutical
1.5xn/a₩230.4b

Price-To-Sales vs Peers: A102460 is expensive based on its Price-To-Sales Ratio (1.5x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does A102460's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
A009290 Kwang Dong Pharmaceutical
0.1xn/aUS$152.45m
A002620 Jeil Pharma Holdings
0.1xn/aUS$78.68m
A000230 Ildong Holdings
0.1xn/aUS$65.61m
No more companies available in this PS range
A102460 1.5xIndustry Avg. 0.8xNo. of Companies14PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A102460 is expensive based on its Price-To-Sales Ratio (1.5x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A102460's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A102460 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A102460's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 07:20
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

REYON Pharmaceutical Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
JooYong KimBookook Securities Co. Ltd